Loncar Cancer Net Asset vs. Beta
CNCR Etf | USD 11.10 0.04 0.36% |
For Loncar Cancer profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Loncar Cancer to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Loncar Cancer Immunotherapy utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Loncar Cancer's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Loncar Cancer Immunotherapy over time as well as its relative position and ranking within its peers.
Loncar |
The market value of Loncar Cancer Immuno is measured differently than its book value, which is the value of Loncar that is recorded on the company's balance sheet. Investors also form their own opinion of Loncar Cancer's value that differs from its market value or its book value, called intrinsic value, which is Loncar Cancer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Loncar Cancer's market value can be influenced by many factors that don't directly affect Loncar Cancer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Loncar Cancer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Loncar Cancer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Loncar Cancer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Loncar Cancer Immuno Beta vs. Net Asset Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Loncar Cancer's current stock value. Our valuation model uses many indicators to compare Loncar Cancer value to that of its competitors to determine the firm's financial worth. Loncar Cancer Immunotherapy is fourth largest ETF in net asset as compared to similar ETFs. It is third largest ETF in beta as compared to similar ETFs . The ratio of Net Asset to Beta for Loncar Cancer Immunotherapy is about 22,304,348 . Comparative valuation analysis is a catch-all technique that is used if you cannot value Loncar Cancer by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Loncar Beta vs. Net Asset
Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Loncar Cancer |
| = | 20.52 M |
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Loncar Cancer |
| = | 0.92 |
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
Loncar Beta Comparison
Loncar Cancer is currently under evaluation in beta as compared to similar ETFs.
Beta Analysis
Loncar Cancer returns are very sensitive to returns on the market. As the market goes up or down, Loncar Cancer is expected to follow.
Loncar Cancer Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Loncar Cancer, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Loncar Cancer will eventually generate negative long term returns. The profitability progress is the general direction of Loncar Cancer's change in net profit over the period of time. It can combine multiple indicators of Loncar Cancer, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the funds index provider, as having a high strategic focus on the development of drugs that harness the bodys own immune system to fight cancer. Loncar Cancer is traded on NASDAQ Exchange in the United States.
Loncar Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Loncar Cancer. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Loncar Cancer position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Loncar Cancer's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Loncar Cancer without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Latest Portfolios Now
Latest PortfoliosQuick portfolio dashboard that showcases your latest portfolios |
All Next | Launch Module |
Use Investing Themes to Complement your Loncar Cancer position
In addition to having Loncar Cancer in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cannabis Thematic Idea Now
Cannabis
Equities that are involved in production and delivery of legal cannabis. This theme is designed for investors that are willing to accept higher levels of market risk inherited by cannabis production and distribution globally. The Cannabis theme has 27 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cannabis Theme or any other thematic opportunities.
View All Next | Launch |
Check out Trending Equities. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
To fully project Loncar Cancer's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Loncar Cancer Immuno at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Loncar Cancer's income statement, its balance sheet, and the statement of cash flows.